Last reviewed 2026-04-23 · How we verify

MT-7117 low dose

MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance.

MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance. Used for Pulmonary arterial hypertension (PAH).

At a glance

Mechanism of action

MT-7117 directly activates soluble guanylate cyclase, an enzyme that produces cyclic guanosine monophosphate (cGMP), a key signaling molecule in vascular smooth muscle relaxation. By increasing cGMP levels, the drug promotes vasodilation and reduces pulmonary vascular resistance, making it potentially beneficial for pulmonary hypertension. The low-dose formulation is designed to optimize tolerability while maintaining therapeutic efficacy.

Approved indications

• Pulmonary arterial hypertension (PAH)

Common side effects

• Headache
• Dizziness
• Hypotension
• Dyspepsia

Key clinical trials

• Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria (PHASE2)
• Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MT-7117 low dose CI brief — competitive landscape report
• MT-7117 low dose updates RSS · CI watch RSS
• Tanabe Pharma America, Inc. portfolio CI